YU34196A - Peptidi i jedinjenja koja se vezuju za receptor - Google Patents

Peptidi i jedinjenja koja se vezuju za receptor

Info

Publication number
YU34196A
YU34196A YU34196A YU34196A YU34196A YU 34196 A YU34196 A YU 34196A YU 34196 A YU34196 A YU 34196A YU 34196 A YU34196 A YU 34196A YU 34196 A YU34196 A YU 34196A
Authority
YU
Yugoslavia
Prior art keywords
peptides
bind
receptor
compounds
peptide mimetics
Prior art date
Application number
YU34196A
Other languages
English (en)
Inventor
Ronald Barrett
William Dower
Steven Cwirla
Sherril Johnson
Christian Gates
Nicholas Wrighton
David Duffin
Christopher Wagstrom
Peter Schatz
Larry Mattheakis
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of YU34196A publication Critical patent/YU34196A/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6811—Selection methods for production or design of target specific oligonucleotides or binding molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Opisani su peptidni i peptidni mimetici koji se vezuju za i aktiviraju trombopoetinski receptor. Ovakvi peptidi i peptidni mimetici su korisni u metodama za lečenje hematoloških poremećaja a naročito, trombocitopenije kao posledice hemioterapije, radijacione terapije, ili transfuzija koštane srži kao i u dijagnostičkim metodama koje koriste obležene peptide i peptidne mimetike.
YU34196A 1995-06-07 1996-06-05 Peptidi i jedinjenja koja se vezuju za receptor YU34196A (sh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US48409095A 1995-06-07 1995-06-07
US47616895A 1995-06-07 1995-06-07
US47812895A 1995-06-07 1995-06-07
US47237195A 1995-06-07 1995-06-07
US48530195A 1995-06-07 1995-06-07
US47360495A 1995-06-07 1995-06-07

Publications (1)

Publication Number Publication Date
YU34196A true YU34196A (sh) 1999-03-04

Family

ID=27560032

Family Applications (1)

Application Number Title Priority Date Filing Date
YU34196A YU34196A (sh) 1995-06-07 1996-06-05 Peptidi i jedinjenja koja se vezuju za receptor

Country Status (5)

Country Link
AU (1) AU6046696A (sh)
HR (1) HRP960256A2 (sh)
MY (1) MY113497A (sh)
WO (1) WO1996040189A1 (sh)
YU (1) YU34196A (sh)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7091311B2 (en) 1996-06-07 2006-08-15 Smithkline Beecham Corporation Peptides and compounds that bind to a receptor
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
HU228582B1 (en) 1998-10-23 2013-04-29 Kirin Amgen Inc Dimeric thrombopoietin peptide mimetics binding to mp1 receptor and having thrombopoietic activity
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
JP4937435B2 (ja) 1998-11-05 2012-05-23 修一 広野 新規化合物およびその医薬用途
WO2000037500A1 (en) * 1998-12-18 2000-06-29 Mount Sinai Hospital Three dimensional structure of a sterile alpha motif domain
AU762351B2 (en) 1999-01-06 2003-06-26 Genentech Inc. Insulin-like growth factor (IGF) I mutant variants
WO2001010891A2 (en) * 1999-08-05 2001-02-15 Research Corporation Technologies, Inc. Il-16 antagonists
EP1149906A1 (en) * 2000-04-25 2001-10-31 Pliva, Farmaceutska, Industrija, Dionicko Drustvo Thrombopoietin receptor modulating peptide
WO2001087323A2 (en) 2000-05-16 2001-11-22 Genentech, Inc. Method for treating cartilage disorders
US7396917B2 (en) 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
AU3400102A (en) 2000-12-05 2002-06-18 Alexion Pharma Inc Rationally designed antibodies
EP1430302A4 (en) * 2001-03-21 2007-08-22 Univ Texas Glycosaminoglycan INHIBITORS
US7332474B2 (en) 2001-10-11 2008-02-19 Amgen Inc. Peptides and related compounds having thrombopoietic activity
WO2004016264A1 (ja) 2002-08-14 2004-02-26 Nissan Chemical Industries, Ltd. トロンボポエチンレセプター活性化剤ならびにそれらの製造方法
ES2462916T3 (es) 2002-09-18 2014-05-26 Janssen Pharmaceuticals, Inc. Métodos para aumentar la producción de células madre hematopoyéticas y plaquetas
TWI324593B (en) 2002-10-09 2010-05-11 Nissan Chemical Ind Ltd Pyrazolone compounds and thrombopoietin receptor activator
CA2525568C (en) 2003-05-12 2017-07-25 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
EA010099B1 (ru) 2003-05-12 2008-06-30 Афимакс, Инк. Пептиды, которые связываются с рецептором к эритропоэтину, и способы их применения
EP2204193A3 (en) 2003-05-12 2010-08-18 Affymax, Inc. Novel spacer moiety for poly(ethylene glycol)-modified peptide-based compounds
TWI351954B (en) 2004-12-08 2011-11-11 Nissan Chemical Ind Ltd Heterocyclic compounds and thrombopoietin receptor
TWI399368B (zh) 2004-12-14 2013-06-21 Nissan Chemical Ind Ltd Amide compounds and thrombopoietin receptor activators
US7550433B2 (en) 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
EP1904472A1 (en) 2005-07-15 2008-04-02 Nissan Chemical Industries, Ltd. Thiophene compounds and thrombopoietin receptor activators
US7960425B2 (en) 2005-07-20 2011-06-14 Nissan Chemical Industries, Ltd. Pyrazole compounds and thrombopoietin receptor activators
EP1947101A4 (en) 2005-11-07 2009-09-16 Nissan Chemical Ind Ltd HYDRAZIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR
EP2025671A4 (en) 2006-06-07 2011-04-06 Nissan Chemical Ind Ltd NITROGENIC HETEROCYCLIC COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR
US7981425B2 (en) 2006-06-19 2011-07-19 Amgen Inc. Thrombopoietic compounds
WO2008028645A1 (en) * 2006-09-05 2008-03-13 Aplagen Gmbh Peptides binding the tpo receptor
EP1897888A1 (en) * 2006-09-05 2008-03-12 AplaGen GmbH Peptides binding the TPO receptor
JP2010520855A (ja) 2007-01-31 2010-06-17 アフィーマックス・インコーポレイテッド 修飾基をポリペプチドおよびその他の高分子に結合するための窒素ベースのリンカー
WO2009029682A1 (en) * 2007-08-28 2009-03-05 Rigel Pharmaceuticals, Inc. Combination therapy with syk kinase inhibitor
EP2492262B1 (en) 2009-10-23 2016-04-20 Nissan Chemical Industries, Ltd. Fused heterocyclic compound and thrombopoietin receptor activator

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198424A (en) * 1989-03-08 1993-03-30 Board Of Regents Of The University Of Oklahoma Functionally active selectin-derived peptides

Also Published As

Publication number Publication date
WO1996040189A1 (en) 1996-12-19
AU6046696A (en) 1996-12-30
MY113497A (en) 2002-03-30
HRP960256A2 (en) 1998-02-28

Similar Documents

Publication Publication Date Title
YU34196A (sh) Peptidi i jedinjenja koja se vezuju za receptor
MX9709315A (es) Peptidos y compuestos que se unen a un receptor de trombopoyetina.
TR200401638T2 (tr) Bir reseptöre bağlanan peptidler ve bileşikler.
PT724456E (pt) Anticorpos contra cd4
NZ324500A (en) Humanized antibodies to human gp39, compositions containing and therapeutic use thereof
AR004357A1 (es) Compuestos de 1-fenil-2-dimetilaminometil-ciclohexan-1-ol, y procedimiento de preparacion para dichos compuestos.
EP0687183A4 (en) SYNERGISTIC COMPOSITION OF A CD4-BASED PROTEIN AND ANTIBODY AGAINST HIV-1, AND METHODS OF USE
EA200001041A1 (ru) Антитела к cd23, их производные и их терапевтическое применение
ES2178000T3 (es) Composiciones y metodos para tratar infecciones usando analogos de indolicidina.
EA200300441A1 (ru) Ассоциация антагониста рецептора св1 и сибутрамина, содержащие их фармацевтические композиции и их применение для лечения ожирения
EP1194164B8 (en) Prion protein peptides and uses thereof
BG110703A (en) PHARMACEUTICAL COMPOSITION, INCLUDING HUMAN ANTIBODIES CONNECTING HUMAN TNF ALPHA AND HIS APPLICATION
GR3026219T3 (en) Mouse monoclonal antibodies
DK0914144T3 (da) Terapeutiske anvendelser af BPI-protein-produkter til human meningokokæmi
PT848720E (pt) Antagonistas da actividade oncogenica da proteina mdm2 e sua utilizacao no tratamento de cancros
ATE280777T1 (de) Bradykinin-antagonist peptide mit n- substituierten glycinen
BG102250A (en) The use of marigold-extracted glycosides for the treatment of psoriasis
ATE69727T1 (de) Zusammensetzung zur behandlung von an haemophilia- a-inhibitor leidenden kranken.
EA200001127A1 (ru) Бактериальные феромоны и их использование
EA200000909A1 (ru) ФОРМА VI 5,6-ДИХЛОР-2-(ИЗОПРОПИЛАМИНО)-1-(b-L-РИБОФУРАНОЗИЛ)-1H-БЕНЗИМИДАЗОЛА
DE69409961D1 (de) Triarylethylenderivate zur therapeutischen verwendung
DE59610098D1 (de) Protein mit anti-tumorwirkung
DE59611353D1 (de) Transketolase-verwandtes protein
RU94026276A (ru) Рецепторы интерлейкина-12 и антител